

March 3, 2023

TO: British Columbia Securities Commission  
Ontario Securities Commission

Dear Sirs/Madams:

**Re: MYND Life Sciences Inc. (the “Corporation”)**

Pursuant to National Instrument 51-102 Continuous Disclosure Obligations, we have reviewed the information contained in the Notice of Change of Auditor of the Company dated February 21, 2023 (“the Notice”) and, based on our knowledge of such information at this time, we agree with the statements made in the Notice pertaining to our firm. We advise that we have no basis to agree or disagree with the comments in the Notice relating to Manning Elliott LLP.

Yours very truly,



Chartered Professional Accountants  
Vancouver, BC